Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Alectinib Edge Over Crizotinib Supported by Patient-Reported Outcomes

April 12th 2018

In findings consistent with earlier results on efficacy and adverse events reported for the phase III ALEX trial, investigators announced superior patient-reported outcomes for the next-generation tyrosine kinase inhibitor alectinib versus the standard of care TKI inhibitor crizotinib in ALK-positive non–small cell lung cancer.

Frontline Atezolizumab Combo Emerges as Potential New Standard in NSCLC

April 12th 2018

The frontline regimen of atezolizumab (Tecentriq), bevacizumab (Avastin), carboplatin, and paclitaxel has emerged as a potential new standard of care for the treatment of patients with metastatic nonsquamous NSCLC.

Atezolizumab Shines in Long-term POPLAR Findings

April 12th 2018

Anti PD-L1 immunotherapy with atezolizumab (Tecentriq) was strongly superior to docetaxel in locally advanced or metastatic non–small cell lung cancer, according to 3-year survival findings from the phase II POPLAR study.

Dr. Goldberg on Sequencing Following Treatment With Osimertinib in NSCLC

April 12th 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses sequencing after therapy with osimertinib (Tagrisso) in EGFR-positive non–small cell lung cancer.

Role of Surgery Could Change Following Durvalumab Approval for Stage III NSCLC

April 11th 2018

Benny Weksler, MD, FACS, discusses the use of surgery in a biomarker-driven and drug-dependent era and highlights other cases in which surgery can benefit patients with NSCLC.

Shifting NSCLC Landscape Creates Confusion for PD-1/Chemo Combo

April 10th 2018

Ari VanderWalde, MD, explains his trepidation with combinations of chemotherapy and immunotherapy in NSCLC.

Frontline Pembrolizumab Improves Survival at Lower PD-L1 Threshold

April 9th 2018

Single-agent treatment with the PD-1 inhibitor pembrolizumab improved overall survival versus chemotherapy as a frontline treatment for patients with locally advanced or metastatic non–small cell lung cancer and a PD-L1 expression level ≥1%.

Dr. Brahmer on Side Effects of Immunotherapy for Lung Cancer

April 7th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing adverse events (AEs) of immunotherapy in lung cancer.

Crizotinib Demonstrates Durable Activity in ROS1+ NSCLC

April 6th 2018

Crizotinib induced a nearly 72% overall response rate and a median progression-free survival of almost 16 months in a single-arm phase II trial of 127 patients with ROS1-positive advanced non–small cell lung cancer (NSCLC).

FDA Grants Dacomitinib Priority Review for Frontline EGFR+ NSCLC

April 4th 2018

The FDA has granted a priority review designation to dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer.

Dr. Goldberg on Options After Developing Resistance to Osimertinib for NSCLC

March 30th 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses options for patients with non

Dr. Lopes Discusses Steroid Side Effects in Lung Cancer Management

March 30th 2018

Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses steroid side effects in lung cancer management.

Weiss Weighs In on Challenges in NSCLC

March 30th 2018

Jared Weiss, MD, shares his insight on challenges in the field of non–small cell lung cancer, such as optimal sequencing.

Surgical Techniques Continue to Evolve in NSCLC

March 29th 2018

Jason M. Long, MD, discusses the latest developments with minimally invasive surgical approaches in the treatment of patients with non–small cell lung cancer (NSCLC).

Durvalumab Success Signifies New Era in Stage III NSCLC

March 28th 2018

Edward S. Kim, MD, recaps the findings from the PACIFIC study of durvalumab and discussed the treatment of patients with stage III NSCLC.

Dr. Wakelee on Available Treatments Following Tumor Progression in Lung Cancer

March 27th 2018

Heather Wakelee, MD, associate professor of Medicine (Oncology) at Stanford University Medical Center, discusses available treatment for patients with lung cancer who progress without a T790M mutation.

Dr. Naidoo on Studies of Immune-Related Adverse Events in Lung Cancer

March 27th 2018

Jarushka Naidoo, MBBCh, assistant professor of oncology, Johns Hopkins University, discusses studies investigating immune-related adverse events for patients with lung cancer.

Dr. Goldberg on Resistance to Osimertinib for NSCLC

March 26th 2018

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses resistance to first- or second-line osimertinib (Tagrisso) for patients with EGFR-mutated non–small cell lung cancer (NSCLC).

Frontline Atezolizumab Regimen Improves Survival in NSCLC

March 26th 2018

Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel significantly improved overall survival compared with bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.

Immunotherapy Combinations Emerging in NSCLC

March 24th 2018

Chad Pecot, MD, discusses the rapidly growing area of combination immunotherapy in non–small cell lung cancer.